Abstract:This study was purposed to preliminarily screen characteristic tumor markers of acute myeloid leukemia (AML) and to investigate the serum proteomics characteristics of patients with AML and their significance in pathogenesis. 14 patients with AML and 28 healthy controls were enrolled in this study. The serum protein components were captured by weak cation exchange nanometer magnetic beads, the protein mass-spectra of all samples were detected by Autoflex II matrix-assisted laser desorption/ionization time of flight mass spectrometer, and the detection data were analyzed by means of CliprotoolsTM2.2 software, then the differential protein molecules were screened and the diagnostic model was established. Sera of 7 AML patients and 14 healthy controls were selected to verify the established model by using blind test. The results indicated that about 69 protein peaks could be detected within the range of 0.7-10 kD in protein spectra of serum samples from AML patients and controls. Compared with healthy controls, there were 44 statistically differential expression peaks in AML group (p<0.0001). Among them, 10 protein peaks were upregulated protein peaks and 34 protein peaks were downregulated. Diagnostic model was established on the basis of Quick Classifier Algorithm (QC), and the three mass peaks had the strongest power for software to automatically distinguish AML group from control group. Mass charge ratios (m/z) were 3216.57, 4089.7, and 7762.87 respectively. Sensitivity was expected as 86.4% while 82.8% in this established model group. Category validation showed that this diagnostic model correctly identified all 6 cases out of AML and 12 cases out of 14 healthy controls. In cross validation, the model sensitivity and specificity both were 85.7%. It is concluded that the AML QC model is composed of three protein peaks, which can effectively distinguish AML patients from healthy controls. Owing to higher sensitivity and specificity, they may act as serum tumor markers of AML. Among the three proteins, the one with m/z 7762.87 is the platelet-derived protein chemokine (PF4) protein. This finding will probably provide significant experimental evidence for understanding pathogenesis, molecular type, prognosis and treatment effect of AML.

Detect of co-expressed protein in MM by laser cofocal scanning microscopy

Study on the Relationship Between Expression of APE1 Gene and Clinical Effect of Multiple Myeloma

Clinical Implications of C-Maf Expression in Plasma Cells from Patients with Multiple Myeloma

Microarray-Based CD38 Peptide Probe Screening for Multiple Myeloma Imaging.

[The Research on the Expression and Localization of Multiple Myeloma Associated Antigen MMSA-1].

Immunohistochemical Detection of Epithelioid Angiomyolipoma of Kidney

The Detection of the Immunophenotyping of Plasma Cells in Patients with Multiple Myeloma

Detection of Myeloma Cell-Derived Microvesicles: a Tool to Monitor Multiple Myeloma Load

[Quantitative Detection and Integrality Analysis of Plasma Circulating Cell-Free DNA in Multiple Myeloma]

[Correlation between Expression Patterns of CD117/CD200 in Plasma Cells and Molecular Genetic Prognostic Parameters in Multiple Myeloma]

Expressions of CD40 and CD138 on surface of myeloma cells

Expression of PRAME Gene in Acute Leukemia and Its Clinical Significance

[PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease]

Simultaneous detection of MDR1 and BAALC gene expression in acute myeloid leukemias and its clinical implication

MMSA-1 expression pattern in multiple myeloma and its clinical significance

[Abnormal Expression of Programmed Cell Death 5 Gene in Multiple Myeloma Patients].

[Preliminarily Screening of Serum Characteristic Markers in Acute Myeloid Leukemia and Clinical Significance].

Proteomic analysis for finding serum pathogenic factors and potential biomarkers in multiple myeloma.

Immunophenotype and its clinical significant of multiple myeloma

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen

EXPRESSION AND ITS SIGNIFICANCE OF miRNA-19 IN MULTIPLE MYELOMA